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Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction and several systemic features. Cardiovascular, pulmonary, psychological, and muscle involvement are the main comorbidities of RA and are responsible for the severity of the disease and long-term prognosis.
Pharmacological treatment of rheumatic diseases has evolved remarkably over the past  years. In addition, the widespread adoption of treat to target and tight control strategies has led to a substantial improvement of outcomes, so that drug-free remission is nowadays a realistic goal in the treatment of RA. However, despite the availability of multiple therapeutic options, up to 40% of patients do not respond to current treatments, including biologics. Small-molecule therapies offer an alternative to biological therapies for the treatment of inflammatory diseases. In the past 5 years, a number of small-molecule compounds targeting Janus kinases (JAKs) have been developed. Since JAKs are essential for cell signaling in immune cells, in particular controlling the response to many cytokines, their inhibitors quickly became a promising class of oral therapeutics that proved effective in the treatment of RA. 
Tofacitinib is the first Janus kinase (JAK) inhibitor approved for the treatment of RA, followed more recently by baricitinib. Several other JAK inhibitors, are currently being tested in phase II and III trials for the treatment of a different autoimmune diseases. Most of these compounds exhibit an overall acceptable safety profile similar to that of biologic agents, with infections being the most frequent adverse event. Apart from tofacitinib, safety data on other JAK inhibitors are still limited. Long-term follow‑up and further research are needed to evaluate the general safety profile and the global risk of malignancy of these small molecules, although no clear association with malignancy has been reported to date. 
Here, we will review the main characteristics of JAK inhibitors, including details on their molecular targets and on the clinical evidences obtained so far in the treatment of RA.  
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that causes progressive articular destruction and several associated extra-articular manifestations such as cardiovascular, hematological, metabolic, and pulmonary complications The disease affects about 0.5-1% of the population, can present at any age, and is more prevalent in women than in men [1]. RA is a prototype of an inflammatory autoimmune disease, characterized by pathological and clinical heterogeneity. The inflammatory process predominantly affects the synovium, and is characterized by chronic synovial inflammation (i.e. synovitis), ultimately leading to the breakdown of cartilage and juxta-articular bone [2]. RA is associated with a significant decline of physical function and quality of life. The consequent functional disability and decreased work capacity and social engagement represent an important social burden. Therefore, an early diagnosis of RA, accompanied by an immediate treatment and a tight disease control are fundamental to improve its outcomes [3]. 
Modern genetic technologies have advanced our understanding of the genetic basis of the disease. More than a hundred susceptibility loci have been associated to the risk of developing RA. Most of these implicate immune mechanisms, and many are shared with other chronic inflammatory diseases [4]. In addition, epigenetic modifications further contribute to the pathogenesis of RA, probably by facilitating the integration of environmental and genetic factors. Among these, for example, altered histone acetylation and DNA methylation have been shown to regulate the biology of synovial fibroblasts and leucocytes [5]. Furthermore, microRNAs (eg, miR146a or miR155) [6], by targeting mRNA for degradation, have been identified as key regulators of the immune cells (i.e. lymphocytes, macrophages, and synovial fibroblasts) involved in the pathogenesis of RA [4, 7]. 
In addition to the genetic predisposition, the development of RA has been associated with several environmental factors. For example, smoking and low socioeconomic status are well known risk factors for RA [8, 9]. Many investigations have also implicated bacterial or viral triggers in the pathogenesis of RA. Recently, periodontitis and the oral microbiota (e.g., Porphyromonas gingivalis), have been proposed as causative factors of RA [10]. 
Most of the symptoms, joint damage and complications of RA are related to the formation of immune complexes (ICs), associated to the presence of autoantibodies such as Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPAs).  In particular, ACPAs are highly specific for RA, are associated with a worse prognosis and can be directly pathogenic, either by activating innate immune cells (i.e. macrophages), by ligating toll-like receptors or Fc-receptors or leading to osteoclast differentiation and bone resorption both in vitro and in vivo [11, 12].  Interestingly, ACPAs have been detected up to 10 years before the actual diagnosis, during the pre-clinical phase of RA (pre-RA), which is suggesting that the breach of tolerance against auto-antigens is a long-term process happening many years before the disease develops [13].   
The onset of clinically apparent RA is characterized by a robust synovial inflammatory response [14]. Initially, this phase is characterized by the de​velopment of arthralgia or joint stiffness without any clinical evidence of arthritis. Finally, some patients develop classical clinical features of RA, which is described as established RA [15]. In this phase, the immune response leads to  synovial inflammation, characterized by a heterogeneous infiltration of both innate and adaptive immune cells, including neutrophils, monocytes, macrophages, mast cells, and lymphocytes [16, 17]. Ultimately, the chronic immune response will lead to the activation of synovial fibroblasts, with progressive extracellular matrix (ECM) invasion and secretion of matrix metalloproteinases (MMPs). If untreated, this will induce the destruction of cartilage and bone, with consequent long-term disability because of the joint damage. Although the cellular and humoral players RA have been extensively characterized, there is a marked heterogeneity in terms of synovial inflammation, with different patterns of synovial inflammation identified and emerging as a potential taxonomic classifier of RA, possibly correlating with a disease progression and response to treatment [18]. 
Similarly, there is a well-known albeit rather complex cytokine milieu that influences a multitude of pathophysiological processes during the development of RA. Activation of osteoclasts, chondrocytes and fibroblasts, in addition to immune effector cells migration into the joint synovium are all modulated by cytokine recruitment. The role of cytokines in the pathogenesis of RA has been studied for over 25 years and the enormous advances in molecular biology and biochemistry in the last two decades highlighted the structure and function of several key receptors and mediators, which have become the target of monoclonal antibodies and similar biological agents. On the other hand, the use of cytokine inhibitors in clinical practice has helped understanding the heterogeneity of the immune response, with a different contribution of each cytokine and/or cell type. For example, it is now well known that TNF and IL-6 are essential in the pathogenesis of RA, while IL-1, despite its expected contribution based on pre-clinical disease model, turned out to be less relevant for RA patients [4, 19]. 
Along with the availability of effective treatments, the implementation of treat-to-target  and tight control strategies has significantly improved the outcomes of patients with RA.  However, up to 40% of patients do not respond to the current therapeutics, including second and third line treatments with biologic agents. Therefore, there is need for a better understanding of the pathogenesis of RA at cellular and molecular level, in order to identify additional therapeutic targets. In this sense, the elucidation of the intracellular signaling pathways on immune cells has led to the development of small molecules targeting key intracellular enzymes, such as tyrosine kinases, which are essential in shaping the immune response (Figure 1). Here, we will summarize the most recent advancements on the use of tyrosine kinase inhibitors in RA.

Role of kinases in cell signaling
Several physiological processes, such as cell growth, migration and differentiation are regulated by a mechanism of phosphorilation [20], which is mediated by enzymes termed kinases. More than 500 kinases have been described; some receptors are themselves kinases whereas other are linked to intracellular kinases [20]. In this context, many receptors of the immune system exert their effects through kinases, thus suggesting the possibility that specific kinase inhibitors might be used  as therapeutic agents in different autoimmune diseases [20, 21]. As the structure of the enzymatic region containing the ATP is remarkably similar between family members, one might think that targeting specific kinases would turn out quite challenging. On the contrary, several small molecules inhibitors have been developed in the last years, with various ranges of specificity toward different kinases [20].
Initially, elegant studies have been performed in the field of oncology [22]. These studies among others have investigated the PI3K pathway as a therapeutic target, and multiple inhibitors have been developed against PI3K and its isoforms, mammalian target of rapamycin (mTOR), protein kinase B/AKT, and other intracellular signals [23]. 
In rheumatic diseases, the most attractive targets are the kinases downstream of cytokine receptors [24]. In particular, activation of Janus kinases or JAKs can regulate the signaling of many type I and type II cytokine receptors, through the binding of the intracellular domains to the different JAKs. Four JAKs have been identified in humans: JAK1, JAK2, JAK3 and non-receptor tyrosine-protein kinase TYK2; JAK1 and JAK2 downstream the signal of different cytokines whereas JAK3 has more limited interactions [25].  JAKs transmit extracellular cytokine signals by activating various combinations of transducers and activators of transcription (STATs). In turn, activated STATs translocate into the nucleus, where they induce transcription of specific genes [26].
Various JAK complexes are known to mediate distinct cytokine signaling pathways [27]. Several interleukins (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) trigger the JAK1-JAK3 complex, essential both for lymphocyte proliferation and homeostasis processes, whereas IL‑6 signaling is mediated by JAK1, JAK2 and TYK2.  JAK1-TYK2 com​plexes are important signaling path​ways in host defense include innate antiviral responses. Other signaling pathways mediated by JAK-STAT are important for cellular homeostasis, including lymphocyte production and erythropoiesis [20]. Because of the various effects of cytokines on different cell types, blocking JAKs will influence several immune cells. 

Effects of JAK inhibitors on immune cells 
As JAK kinases are primarily involved in cytokine signaling, representing the basis of the cross-talk between immune cells, their blockade will influence at different levels various cells of the innate and adaptive immunity. While the details of the clinical testing of JAK inhibitors will be presented in the next paragraph, we will first discuss their differential effects of immune cells relevant in the pathogenesis of RA. Initially, the main candidate for blockade with small molecules was JAK3, because of its known role in lymphocyte development [28]. In fact, mutations in JAK3 were found in patients with Severe Combined Immunodeficiency (SCID) [29]. Accordingly, blocking JAK3 was predicted to suppress the activation of B and T lymphocytes. However, the first drug developed as JAK inhibitor and currently approved in RA, tofacitinib [30, 31], turned out to also inhibit JAK1 and, to a lesser extent, JAK2, while has little effect on TYK2, and on kinases other than JAKs [32] (Figure 2). Tofacitinib, as a potent inhibitor of JAK3, blocks effectively IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 by the common chain c. To a lesser extent, tofacitinib blocks JAK2 and therefore IL-12 and IL-23, as well as IL-3, IL-5, GM-CSF by common β chain. In addition, tofacitinib exerts effects on lymphocytes [33], indeed he blocks Th1 and Th2 cell differentiation and interferes with Th17 cells generation. However, the binding of other JAKs probably represented an advantage, as tofacitinib is also able to inhibit, for example, IL-6 and IFN signaling, because of its effects on JAK1. Accordingly, some of the effects of tofacitinib were shown to be mediated by the inhibition of IFN signaling in fibroblasts [34]. Similarly, the effect on IL-6 signalling potentiates the inhibitory effect of tofacitinib on B cells [35], which are key players of the immune response in RA. The activation of synovial macrophages has also been shown to be affected by tofacitinib [36]. Very recently, tofacitinib was also shown to inhibit mast cell activation [37]. Although the specific impact of tofacitinib on the activation of synovial mast cells has not been investigated, mast cells are known to play a multifaceted yet important role in the pathogenesis of RA, with known pro- [38] and anti-inflammatory effects [38], therefore their inhibition by tofacitinib warrants further investigation. Overall, tofacitinib has a wide impact on the immune response, partially due to the blocking of multiple JAKs, which is accompanied by an acceptable safety profile [24], as discussed in more details in the next paragraphs. A more recently developed Jakinibs, baricitinib, also approved for use in RA patients, has a slightly different affinity profile for JAKs, as it binds JAK1 and 2 with a minimal binding to JAK3. Thus, baricitinib is predicted to inhibit many cytokines, by blocking signaling via the γc chain, the β common chain (IL-3, IL-5 and GM-CSF), gp130 (IL-6 family), interferons, and interleukins (IL-12, IL-23, IL-27). To date, despite of the availability of clnical trials leading to its approval, limited data is available on the specific effects of baricitinib on immune cells. For example, it has been shown very recently that baricitinib can inhibit osteoclastogenesis by suppressing RANKL expression in osteoblasts [39]. 
Overall, despite the initial and ongoing effort to develop specific inhibitors, the wider spectrum of action of currently available Jakinibs might actually represents an advantage, and the acceptable safety profile probably originates from the differential modulation of cytokine signaling, also considering the complexity and redundancy of the JAK-STAT family [26]. However, it is important to consider the different binding profile of the different drugs [28] when assessing their efficacy and safety profiles, which will be discussed in the next paragraphs for each molecule.

JAK inhibitors in clinical practice
Tofacitinib was the first Jakinib approved by the U.S. Food and Drug Administration (FDA) in 2012 for adult patients with established moderate-to-severe RA, who either respond inadequately or are intolerant to MTX [40]. Based on the efficacy and safety trials, tofacitinib has been introduced by 2015 ACR guidelines for the treatment of RA, recommended as a second-line option after DMARD monotherapy [41]. It can be considered as either monotherapy or combination therapy for patients with moderate to high disease activity despite DMARD monotherapy (including MTX) [42, 43].  In February 2017, the European Medicine Agency approved both tofacitinib and baricitinib as a second-line therapy for moderate to severe active rheumatoid arthritis in adults, either alone or in combination with MTX [44, 45]. Importantly, the 2016 update of EULAR recommendations for the management of RA with synthetic and biological disease-modifying antirheumatic drugs, included tofacitinib and baricitinib as second line treatment upon failure of a conventional synthetic DMARD, although treatment with a biological DMARD is suggested as current practice [45]. In the next paragraphs, we will summarize the results of the clinical trials leading to the approval of these drugs.

Tofacitinib
Multiple clinical trials evaluated the efficacy of tofacitinib in RA, inflammatory bowel disease (IBD), psoriasis and renal transplantation [46]. In particular, tofacitinib underwent placebo-controlled clinical trials of twice daily dosing in RA [30, 31, 43] and has been approved for clinical use in over 80 countries at a recommended dose of 5 mg twice a day or 11 mg extended release once a day [44]. In a randomized study, tofacitinib has proved as effective as adalimumab (ACR 20 response rates 51.5%, 52.6%, and 47.2% among patients receiving 5 or 10 mg of tofacitinib or those receiving adalimumab) [42]. In a recent meta-analysis, in patients with moderate-to-severe RA, 5 mg twice a day or 10 mg twice a day of tofacitinib, either as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), showed greater remission and low disease activity rates compared to placebo. Independently of the instrument and indices used, the rates of remission and low disease activity continued to increase at 6 months in each study (ORAL Sync, ORAL Scan, and ORAL Standard), and rates were generally higher for tofacitinib 10 mg twice a day than 5 mg twice a day [47]. The efficacy and safety of tofacitinib as a second-line therapy option in patients with Inadequate response (IR) to csDMARDs (including MTX) even if with no IR to TNFi, have been described [48]. Data of a network meta-analysis based on the available evidence from RCTs show that tofacitinib 5 mg twice a day was more effective than placebo and as effective as bDMARDs. Efficacy was measured by ACR response rates at weeks 12 and 24, with health assessment questionnaire disability index (HAQ-DI) improvement at week 12. Safety of tofacitinib 5 mg BID was assessed by considering the withdrawal rate due to all causes, AEs and risk of AEs and SAEs and resulted similar to the bDMARDs’ [49].  Finally, a recent meta-analysis of 34 studies showed that tofacitinib discontinuation rates were not different from biologics in the cDMARDs-IR group. In the biologics-IR group, however, TNFi and rituximab had significantly lower total discontinuation rates than tofacitinib. As for Loss of Efficacy and Adverse Events, tofacitinib discontinuation rates were comparable to biologics [50].
Encouraging data on the efficacy of tofacitinib in psoriasis and in ulcerative colitis suggest that this drug might have broader applications [46].

Baricitinab
The EMA has recently approved baricitinib, an orally available small molecule, which causes a selective (and reversible) inhibition of JAK1 and JAK2 [51], and has only a moderate activity against TYK2 and significantly less activity against JAK3 [51]. Baricitinib is approved for adult patients with moderate-to-severe active RA who showed poor response or are intolerant to one or more disease-modifying anti-rheumatic drugs [51, 52]. It can be used either as monotherapy or in combination with MTX and it is administered orally, once a day [52]. It has been tested in large phase III clinical trials and seems to be well tolerated [53, 54]. The RA-BUILD study enrolled 684 RA patients with poor response to conventional DMARD therapy and active disease. Baricitinib showed significantly higher ACR 20/50/70 response rates compared with placebo. The improvement in ACR response was corroborated by improvement of HAQ-DI and a slower radiographic progression [53]. 
The RA-BEACON study showed that in RA patients with inadequate response to one or more TNF-inhibitors baricitinib had significantly higher ACR 20 response rates compared to placebo. Higher ACR 50 and ACR 70 response rates were also observed but were not statistically significant. Part of the baricitinib group achieved Disease Activity Score (DAS)-28<2.6, mean HAQ-DI, Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) response rates [52]. In both RA-BUILD and RA-BEACON studies, preliminary data showed that the absence of early clinical response (as indicated by a failure to achieve a decrease in DAS-28>0.6 or CDAI>6) after 4 weeks of treatment was associated with lower chances of achieving of low disease activity or remission at 12 or 24 weeks [53, 54].
In RA-BEGIN trial, baricitinib administered either as monotherapy or in combination with MTX to patients with early, active RA who had limited or no prior treatment with conventional DMARDs, showed higher response in the monotherapy group than in the MTX therapy group. Moreover, combination therapy with MTX did not improve response rates compared to baricitinib monotherapy. However, baricitinib-MTX combination therapy showed a better reduction in radiographic progression versus either MTX or baricitinib monotherapy [54].
Baricitinib compared to adalimumab and placebo in MTX-IR patients in the RA-BEAM trial achieved a significantly higher ACR 20/50/70 response than placebo group and adalimumab at 12 and 24 weeks [55]. In the RA-BEYOND study, a long-term extension study [56], patients who underwent 4 mg once a day baricitinib therapy for at least 15 months, achieving sustained low disease activity or remission were double blind re-randomized and either continued to receive baricitinib 4 mg once a day or stepped down to a 2 mg daily dose. Both groups obtained a lower Disease Activity Score (DAS) or remission rate assessed after 12 weeks.  Although the reduction to 2 mg at week 12 was associated with a statistically significant increasing in DAS-28-C-reactive Protein (CRP), CDAI and SDAI scores.  [56].

Other Jakinibs under evaluation 
Several others Jakinibs in phase III clinical trials are ongoing to test their efficacy and safety in RA [44, 46]. Ruxolitinib is a JAK1/2 inhibitor and has been tested in several autoimmune diseases [46]. 
Ruxolitinib is licensed for the treatment of myelodysplasia, although the suppressive effects of first-generation Jakinibs on haematopoiesis are one of the reason for which trials on RA with ruxolitinib have been discontinued [46]. 
Peficitinib, a pan-Jakinib, is under evaluation for efficacy and safety in combination with limited csDMARDs in patients with moderate-to-severe RA [46]. Second generation Jakinibs are under development for the treatment of different autoimmune diseases, able to inhibit selectively JAK1 or JAK3. This major selectively should in theory have less risk of haematopoietic toxicity- an effect largely secondary to JAK2 inhibition [57], although, as discussed before, higher selectivity might also decrease efficacy. 
Filgotinib is the first JAK1 inhibitor and it may provide limited toxicity. Filgotinib clinical trial data so far seem promising, as it was shown to induce a rapid and sustained response, accompanied by a good profile of safety and tolerability [58]. Filgotinib was in fact is well tolerated and doesn’t appear to have effects on JAK2 signaling. Studies on healthy volunteers with dose regimens up to 450 mg per day showed no adverse events [59].
In 2012, a 4 week phase II A clinical trial analyzed 36 patients with inadequate response to MTX who received either filgotinib 100 mg twice a day, 200 mg once a day or placebo for 4 weeks. Both fligotinib groups achieved significant ACR20 and improvement of DAS-28-CRP  [60]. Another IIA phase study double blind enrolled 91 patients with poor response to MTX and naive to bDMARDS. Patients were administered 30, 75, 150 and 300 mg once a day of filgotinib versus placebo. CRP and DAS-28 were equally improved in all filgotinib groups with minimal clinical efficacy at lower doses compared to 75 to 300 mg groups [61]. The DARWIN 1 study was designed to evaluate efficacy and safety of filgotinib at different doses and regimens in patients with moderate-to-severe active RA with an inadequate response to MTX as add on therapy [62]. At week 12, all filgotinib groups showed a significant difference of  many different composite measures of disease remission or response to treatment (ACR-N, DAS28-CRP, SDAI and European League Against Rheumatism (EULAR) ‘good’ response) when compared to placebo group. 
A more recent phase II b study shows clinical efficacy of filgotinib monotherapy versus placebo in methotrexate (MTX)-IR active RA patients [63]. 

Safety of Jakinibs
Most of the adverse events (AEs) reported of JAK inhib​itors, derive from the use of tofacitinib. In fact, tofacitinib boasts most of the safety data available so far with long-term extension studies including approximately 15,000 person-years of exposure [24]. The most common and important side effects were related to infections,  in particular upper respiratory and opportunistic infections including M. tuberculosis and Herpes zoster. The risk for varicella zoster virus reactivation was increased with the use of tofacitinib and ruxolitinib, but was usually characterized by localized disease [24, 64]. The risk of infection was 1.5-2 folds higher than expected for RA patients with tofacitinib, reporting even higher rates, if compared to bDMARDs, in the Asian population [65].  However, the risk of infection and overall mortality was not significantly different from that observed in patients treated with other targeted immunosuppressive therapies [24]. 
Other common adverse events are represented by increase in cholesterol, transaminases and creatinine levels, as well as reduced neutrophil counts [64]. Cytopenias are more commonly encountered with ruxolitinib than tofacitinib due to its greater ability to inhibit JAK2.  Hyperlipidemia probably reflects the already known dysregulation of cholesterol metabolism in the context of chronic inflammatory diseases. Nevertheless, patients treated with Jakinibs do not appear to have an increased risk for major adverse cardiac events or stroke [24].
Finally, a concern with Jakinibs is a theoretical increased risk for malignancy, because immunosuppression could dampen antitumor immune surveillance. Preliminary studies conducted with tofacitinib in renal transplantation showed that ∼1% of patients developed post-transplant lymphoproliferative disorder [66]. However, an increased risk of lymphoproliferative disorders and other cancers has not been confirmed in studies where patients were treated with the lower doses of tofacitinib used in inflammatory disorders, such as RA and psoriasis. In any case, long-term studies will allow clarifying this question.
A recent integrated analysis reviewed safety of baricitinib in all phase I to phase III studies and in the RA-BEYOND study [66]. No increment of death, malignancies, serious/opportunistic infections, adverse events were noted in 3464 patients (4214 patient-years) exposed to baricitinib. A statistically significant higher rate of herpes zoster in the baricitinib 4 mg group has been reported compared to placebo. Changes in hemoglobin, lymphocytes, transaminases, creatine kinase and creatinine levels have been reported during Baricitinib treatment; however less than 1% of withdrawals were due to these AEs. Furthermore, the risk of adverse events didn’t appear to be increased over time with longer exposure.
In line with its recent development, limited data are available for filgotinib. In DARWIN 1 study all doses and regimens evaluated were well tolerated and treatment-emergent adverse events (TEAEs) were similar for all groups. Drug related TEAEs were observed more frequently in filgotinib groups (20.9%) than in placebo ones (10.7%). Fifteen patients had ≥1 serious TEAE, with one death due to pneumonia and septic shock in the group reciving filgotinib 100 mg twice a day.. Serious TE infections were observed in one patient in the placebo group and in five patients in the filgotinib group. Treatment discontinuation rates were low, with one patient in placebo group and five withdrawals from filgotinib group due to infections. Herpes zoster infections were observed in four patients receiving filgotinib and in one placebo patient [62]. In DARWIN 2 study, all doses of filgotinib evaluated were tolerated and equal number of patients had TEAEs in both placebo and filgotinib groups. Nine serious TEAEs were reported (seven with filgotinib, two with placebo), four of which were serious infections (pneumonia, cellulitis, gastroenteritis and pyelonephritis). There was only one case of herpes zoster infection in a patient receiving filgotinib 50 mg once a day  [63]. No cases of tuberculosis or opportunistic infections, lymphoma or cancer were reported in either of the studies. As regarding risk of malignancies, experience with filgotinib is limited and long-term safety data will be needed to fully evaluate the risk. Patients treated with ruxolitinib for myelofibrosis and polycythemia vera did not presented an increased risk of developing a second malignancy [67]. 

Conclusions: what have we learnt from JAK inhibition? 
RA is usually an insidious disease, very heterogeneous in its clinical presentation and, as recent data demonstrated, also heterogeneous in its pathogenesis, progression and response to treatment. Importantly, if untreated, patients with RA tend to progress with the risk of developing irreversible joint damage and permanent disability. Therefore, an early diagnosis and aggressive treatment is imperative. It is widely accepted that if a treatment is started in the so-called “window of opportunity”, during the first months from its start, the long-term prognosis can be significantly improved. However, despite the availability of effective treatment options, up to 40 percent of patients do not respond to the current treatments.  Although targeted to very specific mediators, these are often used randomly, without a clear pathogenic drive in single patients, hence the high chances of failure. While many studies are focused on developing strategies to predict disease progression and treatment response, in line with a personalized medicine, the development of JAK inhibitors has offered a new approach to the treatment of RA (Table I). In particular, unlike treatments targeting single cytokines or cell types, Jakinibs may act as wider modulators of the immune response, because of their effects on several signaling pathways and thus their ability to suppress different cell types, while at the same time being more specific than traditional immunosuppressors. We are obviously in the first phases of the use of Jakinibs in the treatment of RA and autoimmune diseases. In addition to RA, preclinical data suggest that Jakinibs may be useful in multiple other diseases, including dermatomyositis, chronic actinic dermatitis, erythema multiforme, hypereosinophilic syndrome, cutaneous graft-versus-host disease and systemic lupus erythematosus, among others [68]. In particular, their ability to block the action of type I interferons makes them attractive in SLE [69, 70].
The oral administration of Jakinibs is another strong point. On the other hand, as with any small molecules, Jakinibs cause a less selective effect than their biologic counterparts. Indeed, target specificity is not absolute and may depend on the dose delivered to tissues. Consequently, efficacy and toxicity in the real-life may differ from that predicted from in vitro testing, and even from clinical trials. 
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Figure 1 Timeline of the evolution of treatment for rheumatoid arthritis. 

Gold salts are considered the earliest treatment for rheumatoid arthritis (RA) (1930s); glucocorticoids were  widely used since the 1950s. Methotrexate appeared in  the 1980s. Etanercept, and other anti-TNF agents (infliximab, adalimumab, certolizumab and golimumab) were approved for use in RA from 1998 to 2009; soon followed rituximab targeting B cells, abatacept (co‑stimulatory molecules), tocilizumab (IL-6) and anakinra (IL-1). The more recent agents are the small molecules: apremilast a PDE4 inhibitor and tofacitinib followed by baricitinib as Janus kinase inhibitors.


*Modified from Nat. Rev. Rheumatol. 2017, 13(7), 443-448. 


Figure 2 Schematic representation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. 

After cytokine stimulation JAKs are activated and the phosphorylation of STATs occurs. STATs then dimerize and translocate to the nucleus to activate gene transcription. 

*Modified  from  Kidney Intern. 2012, 82, 1054-1060.


Table I Registry of JAK inhibitors supported clinical studies of human participants conducted around the world. Database ClinicalTrials.gov, Updated 30th September 2017
	Study	Recruitment	Results	Interventions	Characteristics	NCT Number
1	Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	NCT02321930
2	Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis	Recruiting	No Results Available	Tofacitinib	Study Types ObservationalPhase	 NCT03011281
3	A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 3	 NCT02281552
4	Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	 NCT02831855
5	An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective	Active, not recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 3	 NCT02566967
6	Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	 NCT01164579
7	A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With B9ackground Methotrexate	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 2	 NCT02147587
8	Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis	Active, not recruiting	No Results Available	Tofacitinib	Study Types ObservationalPhase	 NCT01932372
9	Effects Of CP-690,550 (Tofacitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 1	 NCT01262118
10	Evaluation of the Condition of Rheumatoid Arthritis After Treatment	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	NCT02157012
11	Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 2	 NCT02996500
12	A Study To Compare The Amount Of Tofacitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	 NCT01184092
13	A Study To Evaluate The Effect Of Food On How Tofacitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tofacitinib (CP-690,550) Tablets To Healthy Subjects	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	 NCT01184001
14	Co-Administration Of Methotrexate And CP-690,550	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 1	 NCT01745055
15	Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	NCT02092467
16	A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	 NCT01741493
17	Korean Post-marketing Surveillance for Xeljanz	Recruiting	No Results Available	Tofacitinib	Study Types ObservationalPhase	NCT02984020
18	Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis	Active, not recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 3	 NCT00413699
19	Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 3	 NCT00661661
20	An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	 NCT02187055
21	Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Anti rheumatic Drugs (DMARDs) In Real Life Conditions	Recruiting	No Results Available	Tofacitinib	Study Types ObservationalPhase	 NCT03073109
22	Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients	Recruiting	No Results Available	Tofacitinib	Study Types InterventionalPhase 4	NCT03016884
23	A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 1	NCT01484561
24	Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	NCT00147498
25	Study Of The Effects Of Atorvastatin On Cholesterol Levels In Rheumatoid Arthritis Patients Taking CP-690,550	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	NCT01059864
26	A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	NCT00976599
27	A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 3	NCT00853385
28	A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	NCT01143805
29	A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)	Not yet recruiting	No Results Available	Tofacitinib	Study Types ObservationalPhase	NCT02797769
30	A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 3	NCT00814307
31	Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550	Completed	Has Results	Tofacitinib	Study Types ObservationalPhase	NCT00414661
32	A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 3	NCT00856544
33	Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	
34	Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	NCT01405118
35	A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate	Completed	Has results	Tofacitinib	Study Types InterventionalPhase 3	NCT00847613
36	A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis	Completed	Has results	Tofacitinib	Study Types InterventionalPhase 2	NCT00550446
37	7 Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors	Completed	Has results	Tofacitinib	Study Types InterventionalPhase 3	NCT00960440
38	Comparison Of 6 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis	Completed	Has results	Tofacitinib	Study Types InterventionalPhase 2	NCT00413660
39	Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in Japan	Completed	Has results	Tofacitinib	Study Types InterventionalPhase 2	NCT00603512
40	A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo	Completed	Has Results	Tofacitinib	Study Types InterventionalPhase 2	NCT01359150
41	Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 3	NCT01039688
42	CP-690,550 Pharmacokinetics In Healthy Chinese Subjects	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	NCT01101919
43	A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	NCT01277991
44	A Study Of The Taste Of Different Oral Liquid Preparations Of CP-690,550 In Trained Adult Product Testers	Completed	No Results Available	Tofacitinib	Study Types InterventionalPhase 1	NCT01023100
45	A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)	Active, not recruiting		Baricitinib 	Study Types InterventionalPhase 3	NCT02265705
46	An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01885078?term=baricitinib&cond=rheumatoid+arthritis&draw=1&rank=2" \o "Show study NCT01885078: An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis​)	Active, not recruiting		Baricitinib	Study Types InterventionalPhase 3	NCT01885078
47	A Moderate to Severe Rheumatoid Arthritis Study (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01721044?term=baricitinib&cond=rheumatoid+arthritis&draw=1&rank=3" \o "Show study NCT01721044: A Moderate to Severe Rheumatoid Arthritis Study​)	Completed		Baricitinib	Study Types InterventionalPhase 3	NCT01721044
48	A Study in Participants With Moderate to Severe Rheumatoid Arthritis (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01711359?term=baricitinib&cond=rheumatoid+arthritis&draw=1&rank=4" \o "Show study NCT01711359: A Study in Participants With Moderate to Severe Rheumatoid Arthritis​)	Completed	Has Results	Baricitinib	Study Types InterventionalPhase 3	NCT01711359
49	A Study in Moderate to Severe Rheumatoid Arthritis Participants	Completed	Has Results	Baricitinib	Study Types InterventionalPhase 3	NCT01721057
50	A Study in Moderate to Severe Rheumatoid Arthritis (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01710358?term=baricitinib&cond=rheumatoid+arthritis&draw=1&rank=6" \o "Show study NCT01710358: A Study in Moderate to Severe Rheumatoid Arthritis​)	Completed	Has Results	Baricitinib	Study Types InterventionalPhase 3	NCT01710358
51	INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs	Completed		Baricitinib	Study Types InterventionalPhase 2	NCT00902486
A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
	Completed	Has Results	Baricitinib	Study Types InterventionalPhase 2	NCT01185353	
Oral JAK1/JAK2 Selective Inhibitor Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
	Completed		Baricitinib	Study Types InterventionalPhase 2	NCT01469013	
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
	Recruiting		Baricitinib	Study Types InterventionalPhase 1/2	NCT02759731	
55	A Relative Bioavailability and Food Effect Study of New Formulations (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01398475?term=baricitinib&cond=rheumatoid+arthritis&draw=1&rank=11" \o "Show study NCT01398475: A Relative Bioavailability and Food Effect Study of New Formulations​)	Completed	Has Results	Baricitinib	Study Types InterventionalPhase 1	NCT01398475
56	A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis	Completed	Has Results	Ruxolitinib	Study Types InterventionalPhase 2	NCT00550043
57	A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to	Active, not recruiting		Peficitinib	Study Types InterventionalPhase 3	NCT02305849
58	A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT01638013?term=Peficitinib&cond=rheumatoid+arthritis&rank=2" \o "Show study NCT01638013: A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K​)	Recruiting		Peficitinib	Study Types InterventionalPhase 3	NCT01638013
59	A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT02308163?term=Peficitinib&cond=rheumatoid+arthritis&rank=3" \o "Show study NCT02308163: A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs​)	Active, not recruiting		Peficitinib	Study Types InterventionalPhase 3	NCT02308163
60	Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis (​https:​/​​/​clinicaltrials.gov​/​ct2​/​show​/​NCT03025308?term=Filgotinib&cond=rheumatoid+arthritis&rank=1" \o "Show study NCT03025308: Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis​)	Recruiting		Filgotinib	Study Types InterventionalPhase 3	NCT03025308
61	Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment	Recruiting		Filgotinib	Study Types InterventionalPhase 3	NCT02873936
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
	Recruiting		Filgotinib	Study Types InterventionalPhase 3	NCT02886728	
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
	Recruiting		Filgotinib	Study Types InterventionalPhase 3	NCT02889796	
64	Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients	Active, not recruiting		Filgotinib	Study Types InterventionalPhase 2	NCT02065700
65	Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate	Active, not recruiting		Filgotinib	Study Types InterventionalPhase 2	NCT02885181
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